Send us Fan Mail

This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn, speaks with Steve Caltrider. Caltrider, Vice President and Chief Intellectual Property Officer at Dana-Farber Cancer Institute and former General Patent Counsel at Eli Lilly, brings perspectives from nonprofit research and pharmaceutical practice to a central question: how does IP help move discoveries from the laboratory to patients? The conversation examines the role of patent protection in supporting investment in life sciences innovation and distinguishes innovation incentives from challenges such as generic drug supply and market concentration.

Caltrider argues that confidence in patent rights depends on improving patent quality at the examination stage. He and Quinn discuss uncertainty around § 101 eligibility for diagnostics and emerging therapies, the effect of PTAB review on investment, and the need to balance error correction with a system that allows innovation to proceed. They also consider how hindsight can distort obviousness analysis and why practitioners should act as stewards of the patent system.

The discussion turns to AI’s potential to improve prior-art searches and give applicants earlier feedback, helping examiners focus on the key issues while preserving human judgment in patentability decisions. Caltrider also explores how simplifying patent law and reducing defensive prosecution practices could enable more candid engagement with examiners. For IP professionals, the conversation offers a practical look at how stronger examination and clearer rules could support more reliable patents and sustained investment.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.